ALX Oncology Q2 net loss $34.2M; terminates MDS/AML programs, delays ALTA-002 IND

ALX ONCOLOGY HOLDINGS INC

2023-Q2 EPS reported -$1.57

GAAP net loss $34.2M ($0.84/share); non-GAAP net loss $27.9M vs $27.1M prior year.
Cash $224.5M; funding expected through mid-2025 plus $40M term loan availability.
Terminating ASPEN-02 (MDS) and ASPEN-05 (AML); evorpacept+azacitidine did not improve outcomes.
ASPEN-06 (gastric cancer) on track for Q4 2023 data update; EU orphan drug designation received.
ALTA-002 IND delayed to Q1 2024 due to CMC issues; ADC platform expansion deferred.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ALX ONCOLOGY HOLDINGS INC reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 10, 2023, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

ALX ONCOLOGY HOLDINGS INC filing history →

Source: SEC EDGAR

accession 0000950170-23-041287

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.